Erschienen in:
21.09.2022 | ASO Author Reflections
ASO Author Reflections: Novel Evidence on Neoadjuvant Chemotherapy for Borderline Resectable Pancreatic Cancer with Arterial Involvement
verfasst von:
Naoki Ikenaga, MD, PhD, Yoshihiro Miyasaka, MD, PhD, Takao Ohtsuka, MD, PhD, Masafumi Nakamura, MD, PhD
Erschienen in:
Annals of Surgical Oncology
|
Ausgabe 1/2023
Einloggen, um Zugang zu erhalten
Excerpt
Neoadjuvant treatment for borderline resectable pancreatic cancer (BRPC) increases the R0 resection rate and improves patient survival when compared with upfront surgery.
1 The optimal regimen and treatment duration of neoadjuvant treatment for BRPC need to be established. BRPC with arterial involvement (BRPC-A) is a subset of BRPC associated with a high rate of margin-positive resection and poor prognosis. The treatment approaches for BRPC-A should be validated separately from those for BRPC-portal vein; however, a BRPC-A-specific analysis of neoadjuvant treatment is lacking. Gemcitabine plus nab-paclitaxel (GnP) therapy has been shown to exert a remarkable effect on primary tumor shrinkage in metastatic pancreatic cancer,
2 along with few severe adverse events when compared with fluorouracil, leucovorin, irinotecan, and oxaliplatin (FOLFIRINOX).
3 Accordingly, GnP could be a promising regimen for neoadjuvant chemotherapy in patients with BRPC. …
